Skip to main content

Myriad Genetics, Inc. (MYGN)

NASDAQ: MYGN · Delayed Price · USD
34.76 0.29 (0.84%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap2.69B
Revenue (ttm)662.30M
Net Income (ttm)-97.30M
Shares Out77.20M
EPS (ttm)0.26
PE Ratio132.67
Forward PE120.48
Dividendn/a
Ex-Dividend Daten/a
Volume277,549
Open34.76
Previous Close34.47
Day's Range33.85 - 35.31
52-Week Range11.76 - 36.95
Beta1.58
AnalystsHold
Price Target30.25 (-13.0%)
Est. Earnings DateNov 9, 2021

About MYGN

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with...

IndustryBiotechnology
IPO DateOct 5, 1995
CEOR. Bryan Riggsbee
Employees2,700
Stock ExchangeNASDAQ
Ticker SymbolMYGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 30.25, which is a decrease of -12.97% from the latest price.

Price Target
$30.25
(-12.97% downside)
Analyst Consensus: Hold

News

Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp

SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select oper...

1 week ago - GlobeNewsWire

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monito...

SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges.

2 weeks ago - GlobeNewsWire

4 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:BHGDDLPX
1 month ago - Benzinga

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

1 month ago - Zacks Investment Research

What's Up With Myriad Genetics Shares Trading Higher Tuesday?

Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported better-than-expected fourth-quarter EPS and sales results. Myriad Genetics r...

1 month ago - Benzinga

Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic G...

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended...

1 month ago - GlobeNewsWire

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score ...

SALT LAKE CITY, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, tod...

1 month ago - GlobeNewsWire

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings confe...

1 month ago - GlobeNewsWire

New research reveals most Americans can't identify the symptoms of depression

GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression GeneSight® Mental Health Monitor finds large gap between what Ameri...

1 month ago - GlobeNewsWire

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement...

2 months ago - GlobeNewsWire

Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units

Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.

2 months ago - Zacks Investment Research

Myriad Genetics Completes Sale of Myriad RBM to IQVIA's Q2 Solutions

SALT LAKE CITY, July 01, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of its wholly-o...

2 months ago - GlobeNewsWire

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role Dr. Slavin Brings Deep Clinical, Academic and Industry Experience to New Role

3 months ago - GlobeNewsWire

Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls

The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narrati...

Other symbols:NSRGYXEC
3 months ago - 24/7 Wall Street

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company's transf...

3 months ago - GlobeNewsWire

Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.

3 months ago - Zacks Investment Research

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsid...

3 months ago - GlobeNewsWire

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

3 months ago - Zacks Investment Research

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

FRESNO, Calif., May 27, 2021 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering fr...

3 months ago - PRNewsWire

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell My...

3 months ago - GlobeNewsWire

Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business

New President Brings Proven Track Record in Women's Health; Direct to Physician and Direct to Patient Commercial Expertise New President Brings Proven Track Record in Women's Health; Direct to Physician...

4 months ago - GlobeNewsWire

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of Al...

Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing Study Is First to Validate New Polygenic Risk Assessment for Al...

4 months ago - GlobeNewsWire

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

4 months ago - Zacks Investment Research